NASDAQ:INFI Infinity Pharmaceuticals (INFI) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free INFI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.01▼$0.1352-Week Range N/AVolume2.48 million shsAverage Volume2.58 million shsMarket Capitalization$726,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Infinity Pharmaceuticals alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Infinity Pharmaceuticals Stock (NASDAQ:INFI)Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.Read More Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 INFI Stock News HeadlinesMarch 16, 2024 | nytimes.comPi Day: How One Irrational Number Made Us ModernMarch 14, 2024 | msn.comBiotech bankruptcies hit a record despite sector’s recoveryApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 13, 2024 | benzinga.comDavid Schnell's Net WorthMarch 11, 2024 | msn.comMemphis Police issue alert after mother and two children abductedJanuary 31, 2024 | finance.yahoo.comStryker Expands Prophecy® Surgical Planning System to Include the New Footprint™, Offering Surgeons a Comprehensive View of the Foot and AnkleDecember 22, 2023 | seekingalpha.comAGNPF Algernon Pharmaceuticals Inc.December 12, 2023 | morningstar.comInfinity Pharmaceuticals Inc INFIQApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…December 1, 2023 | seekingalpha.comINFIQ Infinity Pharmaceuticals, Inc.October 16, 2023 | businesswire.comINFI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities ...October 16, 2023 | barrons.comFINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the FirmOctober 15, 2023 | stockhouse.comInfinity Ongoing Deadline AlertOctober 14, 2023 | bloomberg.comDeadline Alert: Bronstein, Gewirtz & Grossman LLC Announces that Infinity Pharmaceuticals, Inc. (INFI) Investors Have OpportuniOctober 10, 2023 | finance.yahoo.comInfinity Pharmaceuticals, Inc. (INFIQ)October 9, 2023 | barrons.comBronstein, Gewirtz & Grossman LLC Notifies Infinity Pharmaceuticals, Inc. (INFI) Investors of Class Action and to Actively Participate!October 2, 2023 | bizjournals.comGutted Cambridge biotech declares bankruptcy after failed merger, layoffsOctober 1, 2023 | markets.businessinsider.comInfinity Investor Shareholder AlertSeptember 29, 2023 | msn.comInfinity Pharmaceuticals reportedly files for Chapter 11September 22, 2023 | finanznachrichten.deFaron Pharmaceuticals Oy: Faron Pharmaceuticals Announces Board ChangesSeptember 18, 2023 | stockhouse.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 16, 2023 | prnewswire.comINFINITY DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their OptionsSeptember 16, 2023 | markets.businessinsider.comROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFISeptember 15, 2023 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 14, 2023 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 13, 2023 | gurufocus.comDirector Adelene Perkins Sells 410,196 Shares of Infinity Pharmaceuticals Inc (INFI)September 13, 2023 | stockhouse.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSee More Headlines Receive INFI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INFI CUSIP45665G30 CIK1113148 Webwww.infi.com Phone(617) 453-1000Fax617-453-1001Employees30Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,370,000.00 Net Margins-1,593.93% Pretax Margin-1,593.93% Return on EquityN/A Return on Assets-113.02% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$2.59 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / BookN/AMiscellaneous Outstanding Shares90,760,000Free Float81,857,000Market Cap$726,000.00 OptionableOptionable Beta1.63 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Lawrence E. Bloch J.D. (Age 57)M.D., Treasurer Comp: $513.61kMr. Seth A. Tasker J.D. (Age 44)CEO, Sr. VP, Gen. Counsel & Sec. Key CompetitorsBellerophon TherapeuticsNASDAQ:BLPHEvelo BiosciencesNASDAQ:EVLOEvofem BiosciencesNASDAQ:EVFMSciSparcNASDAQ:SPRCAditxtNASDAQ:ADTXView All CompetitorsInsidersAdelene Q PerkinsSold 410,196 sharesTotal: $28,713.72 ($0.07/share) INFI Stock Analysis - Frequently Asked Questions How were Infinity Pharmaceuticals' earnings last quarter? Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The biotechnology company earned $0.43 million during the quarter, compared to the consensus estimate of $0.45 million. During the same period last year, the company earned ($0.16) earnings per share. What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO? 10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Infinity Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX). This page (NASDAQ:INFI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Infinity Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
